KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges: 2011-2023

Historic Amortization of Deferred Charges for Supernus Pharmaceuticals (SUPN) over the last 10 years, with Mar 2023 value amounting to $532,000.

  • Supernus Pharmaceuticals' Amortization of Deferred Charges rose 1.14% to $532,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $2.1 million, marking a year-over-year decrease of 84.73%. This contributed to the annual value of $532,000 for FY2023, which is 74.81% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Amortization of Deferred Charges of $532,000 as of Q1 2023, which was up 0.38% from $530,000 recorded in Q4 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Amortization of Deferred Charges peaked at $4.5 million during Q4 2021, and registered a low of $500,000 during Q2 2022.
  • In the last 3 years, Supernus Pharmaceuticals' Amortization of Deferred Charges had a median value of $532,000 in 2023 and averaged $2.2 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Amortization of Deferred Charges skyrocketed by 528.76% in 2019, and later tumbled by 88.37% in 2022.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Amortization of Deferred Charges stood at $4.0 million in 2019, then increased by 4.82% to $4.2 million in 2020, then climbed by 6.29% to $4.5 million in 2021, then plummeted by 88.13% to $530,000 in 2022, then rose by 1.14% to $532,000 in 2023.
  • Its last three reported values are $532,000 in Q1 2023, $530,000 for Q4 2022, and $529,000 during Q3 2022.